Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Feb 12, 2025
WOBURN, Mass., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2024 and provided a business update.
Read more at globenewswire.com
